Cyclogenix signs licensing and research agreements with Wyeth and IMBcom

Cyclogenix has granted Wyeth exclusive rights to Cyclogenix’s novel drug discovery technology platform for use in generating therapeutic peptides, and Wyeth will fund research activities focused on using these technologies. Wyeth has an option to acquire all rights and ownership to these technologies from Cyclogenix at the end of the research collaboration term, which may run for up to five years, or earlier under certain conditions.

IMBcom has granted Cyclogenix licenses to cyclotide peptide technologies developed by the Institute for Molecular Bioscience (IMB). In addition, under a research agreement, University of Queensland’s David Craik, an expert in cyclotide scaffolds, will collaborate with Cyclogenix in developing cyclotide based drug candidates. The financial terms of the agreements between the parties were not disclosed.

Duncan McGregor, CEO of Cyclogenix, said: “We look forward to building a strong and fruitful relationship with Wyeth and in assisting Wyeth with its therapeutic discovery activities.

“We believe that combining the novel properties of the cyclotide scaffold with Cyclogenix’s expertise in display technologies, provides a powerful new approach for the potential discovery of novel peptides for therapeutic applications.”